News, Links and Commentary
Wednesday, September 06, 2006
Macular Degeneration - A Book For Patients
For many years Dan Roberts has offered support to people, like himself, who have macular degeneration through the MD Support Web site. Dan has sought advice from professionals about new treatments and adaptive technology so that he can offer information to visitors. He has also maintained a forum, discussion list and chat group so that people with MD can support and learn from each other.
Dan's expertise is now available in a book, called The First Year - Age-Related Macular Degeneration: An Essential Guide for the Newly Diagnosed. The subjects he covers include strategies for slowing AMD, current research, approved and experimental treatments, adaptive technology and rehabilitation, coping with depression and stress, and driving and mobility.
The First Year - Age-Related Macular Degeneration: An Essential Guide for the Newly Diagnosed by Daniel L. Roberts is available through Amazon and is published by Marlowe and Company, New York, New York.
(2) comments |
Dan's expertise is now available in a book, called The First Year - Age-Related Macular Degeneration: An Essential Guide for the Newly Diagnosed. The subjects he covers include strategies for slowing AMD, current research, approved and experimental treatments, adaptive technology and rehabilitation, coping with depression and stress, and driving and mobility.
The First Year - Age-Related Macular Degeneration: An Essential Guide for the Newly Diagnosed by Daniel L. Roberts is available through Amazon and is published by Marlowe and Company, New York, New York.
Diary of an MD Patient Treated with Avastin
New Zealander Simon James is about to undergo his second treatment with Avastin for myopic macular degeneration. Simon is 22 years old and significantly younger than most people affected by macular degeneration. You can read about his treatment, which has so far brought positive results, in My Eyes Diary.
Avastin is the drug produced by Genentech and which some ophthalmologists are using as a cheaper alternative to Genentech's Lucentis.
(1) comments |
Avastin is the drug produced by Genentech and which some ophthalmologists are using as a cheaper alternative to Genentech's Lucentis.
